2. Search Result
Search Result
Results for "

Quetiapine-d<sub>8</sub> hemifumarate

" in MedChemExpress (MCE) Product Catalog:

2695

Inhibitors & Agonists

9

Biochemical Assay Reagents

6

Peptides

1

Inhibitory Antibodies

7

Natural
Products

10

Recombinant Proteins

2609

Isotope-Labeled Compounds

3

Antibodies

13

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0031S1
    Quetiapine-d4 hemifumarate

    		5-HT Receptor Dopamine Receptor Neurological Disease
    Quetiapine-d4 (hemifumarate) is the deuterium labeled Quetiapine hemifumarate. Quetiapine hemifumarate is a 5-HT receptors agonist and a dopamine receptor antagonist. Antidepressant and anxiolytic effects[1].
    <em>Quetiapine-d</em>4 <em>hemifumarate</em>
  • HY-B0031S3
    Quetiapine-d8 hemifumarate

    		5-HT Receptor Dopamine Receptor Neurological Disease
    Quetiapine-d8 (hemifumarate) is the deuterium labeled Quetiapine hemifumarate. Quetiapine hemifumarate is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine hemifumarate is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1].
    <em>Quetiapine-d</em><em>8</em> <em>hemifumarate</em>
  • HY-B0031S5
    Quetiapine-d4-1 fumarate

    		Dopamine Receptor 5-HT Receptor Isotope-Labeled Compounds Neurological Disease
    Quetiapine-d4-1 fumarate is deuterated labeled Quetiapine (hemifumarate) (HY-B0031). Quetiapine hemifumarate is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine hemifumarate is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects .
    <em>Quetiapine-d</em>4-1 fumarate
  • HY-B0031S
    Quetiapine-d4 fumarate

    		5-HT Receptor Dopamine Receptor Neurological Disease
    Quetiapine-d4 (fumarate) is the deuterium labeled Quetiapine fumarate. Quetiapine fumarate is a 5-HT receptors agonist and a dopamine receptor antagonist. Antidepressant and anxiolytic effects[1].
    <em>Quetiapine-d</em>4 fumarate
  • HY-137532S
    7-Hydroxy Quetiapine-d8

    		Isotope-Labeled Compounds Drug Metabolite Neurological Disease
    7-Hydroxy Quetiapine-d8 is the deuterium labeled 7-Hydroxyquetiapine. 7-Hydroxyquetiapine (ICI 214227) is the major active metabolite of antipsychotic medicine Quetiapine[1].
    7-Hydroxy <em>Quetiapine-d</em><em>8</em>
  • HY-B0031S4
    Quetiapine hemifumarate-d8

    		Dopamine Receptor 5-HT Receptor Neurological Disease
    Quetiapine (hemifumarate)-d8 is the deuterium labeled Quetiapine hemifumarate[1]. Quetiapine hemifumarate is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine hemifumarate is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[2].
    <em>Quetiapine</em> <em>hemifumarate</em>-d<em>8</em>
  • HY-B0031S2
    Quetiapine-d8 fumarate

    		5-HT Receptor Dopamine Receptor Neurological Disease
    Quetiapine-d8 (fumarate) is the deuterium labeled Quetiapine. Quetiapine is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1][2].
    <em>Quetiapine-d</em><em>8</em> fumarate
  • HY-B0031R
    Quetiapine hemifumarate (Standard)

    		5-HT Receptor Dopamine Receptor Neurological Disease
    Quetiapine (hemifumarate) (Standard) is the analytical standard of Quetiapine (hemifumarate). This product is intended for research and analytical applications. Quetiapine hemifumarate is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine hemifumarate is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects .
    <em>Quetiapine</em> <em>hemifumarate</em> (Standard)
  • HY-12177S
    Aliskiren-d6 hemifumarate

    CGP 60536 d<sub>6sub> hemifumarate; CGP60536B d<sub>6sub> hemifumarate; SPP 100 d<sub>6sub> hemifumarate

    		 Isotope-Labeled Compounds Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren-d6 (hemifumarate) is a deuterium labeled Aliskiren hemifumarate. Aliskiren hemifumarate is a direct and orally active renin inhibitor with an IC50 of 1.5 nM[1][2].
    Aliskiren-d6 <em>hemifumarate</em>
  • HY-B0031
    Quetiapine hemifumarate
    1 Publications Verification

    		 5-HT Receptor Dopamine Receptor Neurological Disease
    Quetiapine hemifumarate is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine hemifumarate is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects .
    <em>Quetiapine</em> <em>hemifumarate</em>
  • HY-137532S1
    7-Hydroxyquetiapine-d4 hemifumarate

    		Isotope-Labeled Compounds Neurological Disease
    7-Hydroxyquetiapine-d4 (hemifumarate) is deuterium labeled 7-Hydroxyquetiapine. 7-Hydroxyquetiapine (ICI 214227) is the major active metabolite of antipsychotic medicine Quetiapine[1].
    7-Hydroxyquetiapine-d4 <em>hemifumarate</em>
  • HY-RS13999
    SUB1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SUB1 Human Pre-designed siRNA Set A contains three designed siRNAs for SUB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SUB1 Human Pre-designed siRNA Set A
    SUB1 Human Pre-designed siRNA Set A
  • HY-146227
    DNA topoisomerase II inhibitor 1

    		Topoisomerase Apoptosis Cancer
    DNA topoisomerase II inhibitor 1 (compound 8ed) is a potent DNA topoisomerase II inhibitor. DNA topoisomerase II inhibitor 1 shows anti-proliferative activity. DNA topoisomerase II inhibitor 1 induces apoptosis and cell cycle arrest at sub G1 phase .
    DNA topoisomerase II inhibitor 1
  • HY-101327A
    Xamoterol hemifumarate

    Corwin hemifumarate; ICI 118587 hemifumarate
    Xamoterol hemifumarate is a selective and potent agonist of beta1-adrenergic receptor. Xamoterol hemifumarate has the potential for the research of arrhythmogenesis. Xamoterol hemifumarate has the potential for the investigating the relationship between β1-adrenergic stimulation and IKr .
    Xamoterol <em>hemifumarate</em>
  • HY-103540
    Tabimorelin hemifumarate

    NN703 hemifumarate

    		 Cytochrome P450 Endocrinology
    Tabimorelin (NN703) hemifumarate is an orally active growth hormone (GH) secretagogue. Tabimorelin hemifumarate is also a potent inhibitor of CYP3A4 activity .
    Tabimorelin <em>hemifumarate</em>
  • HY-15232B
    Tenofovir alafenamide hemifumarate
    5 Publications Verification

    GS-7340 hemifumarate

    		 HIV Reverse Transcriptase Infection
    Tenofovir alafenamide hemifumarate (GS-7340 hemifumarate) is an investigational oral proagent of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor.
    Tenofovir alafenamide <em>hemifumarate</em>
  • HY-135827A
    Roginolisib hemifumarate

    MSC2360844 hemifumarate; IOA-244 hemifumarate

    		 PI3K Inflammation/Immunology Cancer
    Roginolisib (MSC2360844) hemifumarate is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. Roginolisib hemifumarate shows highly selective against a panel of 278 additional kinases .
    Roginolisib <em>hemifumarate</em>
  • HY-100490A
    Rilmenidine hemifumarate

    		Imidazoline Receptor Adrenergic Receptor Apoptosis Autophagy Cardiovascular Disease Cancer
    Rilmenidine hemifumarate, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine hemifumarate is an alpha 2-adrenoceptor agonist. Rilmenidine hemifumarate induces autophagy. Rilmenidine hemifumarate acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na +/H + antiport. Rilmenidine hemifumarate modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells .
    Rilmenidine <em>hemifumarate</em>
  • HY-B0076S
    Bisoprolol-d7 hemifumarate

    		Adrenergic Receptor Inflammation/Immunology Endocrinology
    Bisoprolol-d7 (hemifumarate) is the deuterium labeled Bisoprolol hemifumarate. Bisoprolol hemifumarate is a selective type β1 adrenergic receptor blocker.
    Bisoprolol-d7 <em>hemifumarate</em>
  • HY-12177
    Aliskiren hemifumarate
    5+ Cited Publications

    CGP 60536 hemifumarate; CGP60536B hemifumarate; SPP 100 hemifumarate

    		 Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren (CGP 60536; CGP60536B; SPP 100) hemifumarate is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hemifumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren <em>hemifumarate</em>
  • HY-15293B
    JTV-519 hemifumarate

    K201 hemifumarate

    		 Calcium Channel Cardiovascular Disease
    JTV-519 hemifumarate (K201 hemifumarate) is a Ca 2+-dependent blocker of sarcoplasmic reticulum Ca 2+-stimulated ATPase (SERCA) and a partial agonist of ryanodine receptors in striated muscle. Antiarrhythmic and cardioprotective properties .
    JTV-519 <em>hemifumarate</em>
  • HY-12355A
    Siponimod hemifumarate

    BAF-312 hemifumarate

    		 LPL Receptor Neurological Disease Inflammation/Immunology
    Siponimod (BAF-312) hemifumarate is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod hemifumarate is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC50s of 0.39, 0.98, >10000, >1000, and 750 nM, respectively). Siponimod hemifumarate can be used for multiple sclerosis (MS) research .
    Siponimod <em>hemifumarate</em>
  • HY-13064A
    Cobimetinib hemifumarate
    30+ Cited Publications

    GDC-0973 hemifumarate; XL-518 hemifumarate

    		 MEK Apoptosis Cancer
    Cobimetinib hemifumarate is a novel selective MEK1 inhibitor, and the IC50 value against MEK1 is 4.2 nM.
    Cobimetinib <em>hemifumarate</em>
  • HY-19578B
    Isamoltane hemifumarate

    Isamoltane hemifumarate is a selective antagonist of 5-HT1B receptor, with an IC50 of 39 nM for inhibits the binding of [ 125I]ICYP to 5-HT1B recognition sites in rat brain membranes. Isamoltane hemifumarate is also a β-adrenoceptor ligand, with an IC50 of 8.4 nM. Isamoltane hemifumarate shows anxiolytic activity .
    Isamoltane <em>hemifumarate</em>
  • HY-10844S1
    Pretomanid-d5

    PA-824-d<sub>5sub>; (S)-PA 824-d<sub>5sub>

    		 Antibiotic Bacterial Isotope-Labeled Compounds Infection Cancer
    Pretomanid-d5 is deuterated labeled Pretomanid (HY-10844). Pretomanid (PA-824) is an antibiotic used for the research of multi-drug-resistant tuberculosis affecting the lungs. Pretomanid exhibits a sub-micromolar MIC against M. tuberculosis (MTB). The MIC values of PA-824 against a panel of MTB pan-sensitive and Rifampin mono-resistant clinical isolates range from 0.015 to 0.25 μg/mL.
    Pretomanid-d5
  • HY-114153A
    PLX5622 hemifumarate
    Maximum Cited Publications
    38 Publications Verification

    		 c-Fms Neurological Disease
    PLX5622 hemifumarate is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 µM; Ki=5.9 nM). PLX5622 hemifumarate allows for extended and specific microglial elimination, preceding and during pathology development. PLX5622 hemifumarate demonstrates desirable PK properties in varies animals .
    PLX5622 <em>hemifumarate</em>
  • HY-145723B
    MAX-40279 hemifumarate

    		FLT3 FGFR Inflammation/Immunology Cancer
    MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) .
    MAX-40279 <em>hemifumarate</em>
  • HY-B0076
    Bisoprolol hemifumarate
    5 Publications Verification

    		 Adrenergic Receptor Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Bisoprolol hemifumarate is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol hemifumarate has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .
    Bisoprolol <em>hemifumarate</em>
  • HY-12432A
    Gilteritinib hemifumarate
    20+ Cited Publications

    ASP2215 hemifumarate

    		 FLT3 TAM Receptor Cancer
    Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively.
    Gilteritinib <em>hemifumarate</em>
  • HY-120829S
    Bisoprolol-d5 hemifumarate

    		Adrenergic Receptor Isotope-Labeled Compounds Others
    Bisoprolol-d5 (hemifumarate) is deuterium labeled Bisoprolol (fumarate).
    Bisoprolol-d5 <em>hemifumarate</em>
  • HY-B0615AS
    Moricizine-d8(Hydrochloride)

    EN 313-d<sub>8sub>; Ethmozin-d<sub>8sub>; Moracizine-d<sub>8sub>

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Moricizine-d8 (Hydrochloride) is the deuterium labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period[1][2].
    Moricizine-d<em>8</em>(Hydrochloride)
  • HY-G0021S
    N-Desmethylclozapine-d8

    Norclozapine-d<sub>8sub>; Desmethylclozapine-d<sub>8sub>; Normethylclozapine-d<sub>8sub>

    		 mAChR Opioid Receptor Drug Metabolite Virus Protease Infection
    N-Desmethylclozapine-d8 is the deuterium labeled N-Desmethylclozapine. N-Desmethylclozapine is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine is also a δ-opioid agonist[1][2].
    N-Desmethylclozapine-d<em>8</em>
  • HY-G0021S1
    N-Desmethylclozapine-d8 hydrochloride

    Norclozapine-d<sub>8sub> hydrochloride; Desmethylclozapine-d<sub>8sub> hydrochloride; Normethylclozapine-d<sub>8sub> hydrochloride

    		 mAChR Opioid Receptor Drug Metabolite Virus Protease Infection
    N-Desmethylclozapine-d8 (hydrochloride) is the deuterium labeled N-Desmethylclozapine hydrochloride. N-Desmethylclozapine hydrochloride is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine hydrochloride is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine hydrochloride is also a δ-opioid agonist[1][2][3].
    N-Desmethylclozapine-d<em>8</em> hydrochloride
  • HY-17037S1
    Pirenzepine-d8 dihydrochloride

    LS 519-d<sub>8sub> dihydrochloride; Pirenzepin-d<sub>8sub> dihydrochloride; Gastrozepin-d<sub>8sub> dihydrochloride

    		 Isotope-Labeled Compounds Cancer
    Pirenzepine-d8 (LS 519-d8; Pirenzepin-d8) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .
    Pirenzepine-d<em>8</em> dihydrochloride
  • HY-17037S
    Pirenzepine-d8

    LS 519-d<sub>8sub> free base; Pirenzepin-d<sub>8sub>; Gastrozepin-d<sub>8sub>

    		 Isotope-Labeled Compounds mAChR Neurological Disease Inflammation/Immunology
    Pirenzepine-d8 is the deuterium labeled Pirenzepine dihydrochloride. Pirenzepine dihydrochloride (LS519) is a selective M1 muscarinic receptor antagonist.
    Pirenzepine-d<em>8</em>
  • HY-10227S
    Bortezomib-d8

    PS-341-d<sub>8sub>; LDP-341-d<sub>8sub>; NSC 681239-d<sub>8sub>

    		 Proteasome NF-κB Apoptosis Autophagy Cancer
    Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].
    Bortezomib-d<em>8</em>
  • HY-13011S
    Alectinib-d8

    CH5424802-d<sub>8sub>; RO5424802-d<sub>8sub>; AF802-d<sub>8sub>

    		 Anaplastic lymphoma kinase (ALK) Cancer
    Alectinib-d8 is the deuterium labeled Alectinib. Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively[1]. Alectinib demonstrates effective central nervous system (CNS) penetration[2].
    Alectinib-d<em>8</em>
  • HY-13463BS
    Avatrombopag-d8 hydrochloride

    AKR-501-d<sub>8sub> hydrochloride; E5501-d<sub>8sub> hydrochloride; YM477-d<sub>8sub> hydrochloride

    		 Isotope-Labeled Compounds Thrombopoietin Receptor Cardiovascular Disease
    Avatrombopag-d8 (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].
    Avatrombopag-d<em>8</em> hydrochloride
  • HY-14740S
    Elvitegravir-d8

    GS-9137-d<sub>8sub>; JTK-303-d<sub>8sub>; D06677-d<sub>8sub>

    		 Isotope-Labeled Compounds HIV Integrase HIV Infection
    Elvitegravir-d8 is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
    Elvitegravir-d<em>8</em>
  • HY-15531S
    Venetoclax-d8

    ABT-199-d<sub>8sub>; GDC-0199-d<sub>8sub>; RG7601-d<sub>8sub>

    		 Bcl-2 Family Autophagy Cancer
    Venetoclax-d8 is deuterium labeled Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy[1][2][3].
    Venetoclax-d<em>8</em>
  • HY-110129
    Eplivanserin hemifumarate

    SR-46349 hemifumarate; SR 46349B

    		 5-HT Receptor Neurological Disease
    Eplivanserin (SR-46349) hemifumarate is a potent, selective and orally active 5-HT2A receptor antagonist, with an IC50 of 5.8 nM in rat cortical membrane, and a Kd of 1.14 nM. Eplivanserin hemifumarate displays >20-fold selectivity more selective for 5-HT2A than 5-HT2B and 5-HT2C .
    Eplivanserin <em>hemifumarate</em>
  • HY-15581S
    MMAD-d8

    Demethyldolastatin 10-d<sub>8sub>; Monomethylauristatin D-d<sub>8sub>; Monomethyl Dolastatin 10-d<sub>8sub>

    		 ADC Cytotoxin Microtubule/Tubulin Cancer
    MMAD-d8D is a deuterated form of MMAD, which is a microtubule disrupting agent.
    MMAD-d<em>8</em>
  • HY-Y1309S
    1-Naphthol-d8

    Furro ER-d<sub>8sub>; NSC 9586-d<sub>8sub>; Nako TRB-d<sub>8sub>

    		 Endogenous Metabolite Others
    1-Naphthol-d8 is the deuterium labeled 1-Naphthol[1]. 1-naphthol is an excited state proton transfer (ESPT) fluorescent molecular probe[2].
    1-Naphthol-d<em>8</em>
  • HY-B0272S1
    Rifampicin-d8

    Rifampin-d<sub>8sub>; Rifamycin AMP-d<sub>8sub>

    		 Bacterial Influenza Virus Antibiotic Infection
    Rifampicin-d8 (Rifampin-d8) is the deuterium labeled Rifampicin. Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities.
    Rifampicin-d<em>8</em>
  • HY-N0378S
    D-Mannitol-d8

    Mannitol-d<sub>8sub>; Mannite-d<sub>8sub>

    		 Endogenous Metabolite Apoptosis Metabolic Disease
    D-Mannitol-d8 is the deuterium labeled D-Mannitol. D-Mannitol is an osmotic diuretic agent and a weak renal vasodilator.
    D-Mannitol-d<em>8</em>
  • HY-13502S
    Mitoxantrone-d8

    Mitozantrone-d<sub>8sub>; NSC 301739-d<sub>8sub>

    		 Isotope-Labeled Compounds Topoisomerase PKC Cancer
    Mitoxantrone-d8 (mitozantrone-d8) is the deuterium labeled Mitoxantrone. Mitoxantrone is a topoisomerase II inhibitor and also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM[1][2].
    Mitoxantrone-d<em>8</em>
  • HY-N0007S
    Bisdemethoxycurcumin-d8

    Curcumin III-d<sub>8sub>; Didemethoxycurcumin-d<sub>8sub>

    		 Apoptosis Autophagy Cancer
    Bisdemethoxycurcumin-d8 is the deuterium labeled Bisdemethoxycurcumin. Bisdemethoxycurcumin(Curcumin III; Didemethoxycurcumin) is a natural derivative of curcumin with anti-inflammatory and anti-cancer activities.
    Bisdemethoxycurcumin-d<em>8</em>
  • HY-N0623S5
    L-Tryptophan-d8

    Tryptophan-d<sub>8sub>; Tryptophane-d<sub>8sub>

    		 Endogenous Metabolite Metabolic Disease
    L-Tryptophan-d8 is the deuterium labeled L-Tryptophan. L-Tryptophan (Tryptophan) is an essential amino acid that is the precursor of serotonin, melatonin, and vitamin B3[1].
    L-Tryptophan-d<em>8</em>
  • HY-B0246S2
    Carbamazepine-d8

    CBZ-d<sub>8sub>; NSC 169864-d<sub>8sub>

    		 Sodium Channel Autophagy Mitophagy Neurological Disease Cancer
    Carbamazepine-d8 is the deuterium labeled Carbamazepine. Carbamazepine, a sodium channel blocker, is an anticonvulsant agent, with an IC50 of 131 μM[1][2].
    Carbamazepine-d<em>8</em>
  • HY-13502AS
    Mitoxantrone-d8 dihydrochloride

    Mitozantrone-d<sub>8sub>(dihydrochloride); NSC 301739-d<sub>8sub> dihydrochloride

    		 Endogenous Metabolite PKC Apoptosis Topoisomerase Orthopoxvirus Isotope-Labeled Compounds Infection Cancer
    Mitoxantrone-d8 dihydrochloride is deuterated labeled Mitoxantrone dihydrochloride (HY-13502A). Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .
    Mitoxantrone-d<em>8</em> dihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: